185 related articles for article (PubMed ID: 37646524)
21. Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant
Tong E; Zhou Y; Liu Z; Zhu Y; Zhang M; Wu K; Pan J; Jiang J
Infect Drug Resist; 2023; 16():6951-6963. PubMed ID: 37928607
[TBL] [Abstract][Full Text] [Related]
22. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
Liu Y; Gao M; Du J; Wang L; Gao J; Shu W; Wang Y; Xue Z; Li L; Pang Y
Clin Infect Dis; 2021 Nov; 73(9):e3391-e3397. PubMed ID: 32667984
[TBL] [Abstract][Full Text] [Related]
23. Acquired resistance of Mycobacterium tuberculosis to bedaquiline.
Andries K; Villellas C; Coeck N; Thys K; Gevers T; Vranckx L; Lounis N; de Jong BC; Koul A
PLoS One; 2014; 9(7):e102135. PubMed ID: 25010492
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
[TBL] [Abstract][Full Text] [Related]
25. Investigation of bedaquiline resistance and genetic mutations in multi-drug resistant Mycobacterium tuberculosis clinical isolates in Chongqing, China.
Hu Y; Fan J; Zhu D; Liu W; Li F; Li T; Zheng H
Ann Clin Microbiol Antimicrob; 2023 Feb; 22(1):19. PubMed ID: 36855179
[TBL] [Abstract][Full Text] [Related]
26. Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
Salifu EY; Agoni C; Olotu FA; Soliman MES
Comput Biol Chem; 2020 Apr; 85():107204. PubMed ID: 31981966
[TBL] [Abstract][Full Text] [Related]
27. Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in
Guo Q; Bi J; Lin Q; Ye T; Wang Z; Wang Z; Liu L; Zhang G
Front Cell Infect Microbiol; 2022; 12():807095. PubMed ID: 35694543
[TBL] [Abstract][Full Text] [Related]
28. Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China.
Li G; Xu Z; Jiang Y; Liu H; Zhao LL; Li M; Xu D; Zhao X; Liu Z; Wang R; Wan K
Int J Antimicrob Agents; 2019 Nov; 54(5):642-646. PubMed ID: 31200023
[TBL] [Abstract][Full Text] [Related]
29. The TetR Family Transcription Factor MAB_2299c Regulates the Expression of Two Distinct MmpS-MmpL Efflux Pumps Involved in Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus.
Gutiérrez AV; Richard M; Roquet-Banères F; Viljoen A; Kremer L
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332077
[No Abstract] [Full Text] [Related]
30. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
[TBL] [Abstract][Full Text] [Related]
31. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
[TBL] [Abstract][Full Text] [Related]
32. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
Kadura S; King N; Nakhoul M; Zhu H; Theron G; Köser CU; Farhat M
J Antimicrob Chemother; 2020 Aug; 75(8):2031-2043. PubMed ID: 32361756
[TBL] [Abstract][Full Text] [Related]
33. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era.
Beckert P; Sanchez-Padilla E; Merker M; Dreyer V; Kohl TA; Utpatel C; Köser CU; Barilar I; Ismail N; Omar SV; Klopper M; Warren RM; Hoffmann H; Maphalala G; Ardizzoni E; de Jong BC; Kerschberger B; Schramm B; Andres S; Kranzer K; Maurer FP; Bonnet M; Niemann S
Genome Med; 2020 Nov; 12(1):104. PubMed ID: 33239092
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
35. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.
Almeida D; Ioerger T; Tyagi S; Li SY; Mdluli K; Andries K; Grosset J; Sacchettini J; Nuermberger E
Antimicrob Agents Chemother; 2016 Aug; 60(8):4590-9. PubMed ID: 27185800
[TBL] [Abstract][Full Text] [Related]
36. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
[TBL] [Abstract][Full Text] [Related]
37. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
[TBL] [Abstract][Full Text] [Related]
38. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
[TBL] [Abstract][Full Text] [Related]
39. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
Li R; Ma JB; Yang H; Yang H; Yang XJ; Wu YQ; Ren F
Microbiol Spectr; 2023 Aug; 11(4):e0104823. PubMed ID: 37310268
[TBL] [Abstract][Full Text] [Related]
40. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
